NMN and NR Supplements in Children Under 12: School and Activity Considerations

What Are NMN and NR, and Why Are Parents Asking About Them?

NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are biosynthetic precursors to NAD+ (nicotinamide adenine dinucleotide), a coenzyme central to cellular energy metabolism, DNA repair, and circadian regulation. Both compounds have generated significant adult research interest, but neither has been studied in randomized trials involving healthy children under 12.

Parent interest typically stems from three sources: observational reports of improved adult energy and focus, aggressive supplement-industry marketing that rarely age-gates its claims, and genuine concern about children who seem fatigued or who underperform academically or athletically. Understanding the actual biology, and the genuine gaps in safety data, is essential before any decision is made.

How NAD+ Metabolism Works in Children

NAD+ is synthesized through multiple pathways. The salvage pathway, which NMN and NR enter, converts these precursors via NAMPT (nicotinamide phosphoribosyltransferase) and NRK (NR kinases) into NAD+ inside cells [1]. In children, basal cellular NAD+ concentrations are not depleted the way they are in aging adults. The decline of NAD+ with age is well documented in rodent models and human cross-sectional data [2], but that decline begins meaningfully in middle adulthood, not in childhood.

Why Adult Rationale Does Not Transfer to Children

The primary rationale for NMN and NR supplementation in adults is to restore NAD+ that has declined with aging, mitochondrial dysfunction, or metabolic disease. A child's NAD+ biosynthetic capacity is largely intact. Supplementing a system that is already operating normally introduces precursor load without a clear physiological need, and the downstream consequences, including effects on SIRT1, PARP enzymes, and CD38 activity, have not been characterized in a developing pediatric system [3].

Is There Any Clinical Evidence for NMN or NR in Children Under 12?

The short answer is no. As of the date of this article's review, no published peer-reviewed randomized controlled trial has enrolled healthy children under age 12 to test NMN or NR supplementation for any outcome, including cognition, physical performance, or fatigue [4].

What the Adult Trial Field Shows

Adult trials do exist and are instructive for understanding context. A 2023 randomized, double-blind, placebo-controlled trial by Yoshino et al. (N=25, postmenopausal women) found that NMN 250 mg/day for 10 weeks increased muscle insulin sensitivity and NAD+ metabolite levels [5]. The STEP-equivalent benchmark for NMN does not exist in pediatrics. A 2020 phase I safety trial by Irie et al. (N=10, healthy adult men, ages 40-60) found single oral doses of NMN up to 500 mg were safe in adults without serious adverse events [6]. Neither of these trials provides any basis for extrapolating pediatric dosing or safety.

ClinicalTrials.gov Search Results

A search of ClinicalTrials.gov for "NMN children" or "nicotinamide riboside pediatric" returns no completed or active trials involving healthy children under 12 for performance or cognitive outcomes [4]. There are limited investigations in specific pediatric disease contexts, such as mitochondrial disorders, but these are experimental, not approved, and are conducted under strict IRB and FDA oversight with informed consent requirements that would not apply to over-the-counter supplement use.

What Gaps Mean for Decision-Making

Absence of trials is not neutral. Regulatory agencies including the FDA apply the principle that lack of pediatric data is itself a safety signal [7]. The FDA's Pediatric Research Equity Act requires drug sponsors to assess pediatric safety, precisely because children are not simply small adults and extrapolation from adult pharmacokinetics is unreliable [7].

School Performance: Can NMN or NR Help a Child Focus or Learn Better?

There is no clinical evidence that NMN or NR improves cognitive performance, attention, memory, or academic outcomes in children under 12. None.

The NAD+-Cognition Link in Adults

In adults, some preclinical data suggest that maintaining NAD+ levels supports neuronal function and may reduce neuroinflammation [8]. A 2021 review in Aging Cell noted that NAD+ repletion in aged mouse models improved cognitive flexibility and hippocampal plasticity [9]. These findings come from animal models with induced NAD+ deficiency, a state not present in healthy school-age children.

ADHD, Fatigue, and Supplement Marketing

Some marketing materials position NAD+ precursors alongside claims about focus and energy in children. The American Academy of Pediatrics has noted broadly that dietary supplements marketed for cognitive enhancement in children lack sufficient safety and efficacy data and should not be used without physician oversight [10]. No AAP or CDC guideline endorses NMN or NR for pediatric cognition [10].

What Actually Supports School Performance in This Age Group

Evidence-based interventions for cognitive performance in children under 12 include adequate sleep (the CDC recommends 9-12 hours per night for ages 6-12) [11], iron-sufficiency screening given that iron-deficiency anemia affects approximately 5.9% of children aged 1-5 in the U.S. [12], regular aerobic physical activity, and vitamin D repletion where deficient. These are documented, safe, and guideline-supported. NMN and NR are not in this category.

Sports and Physical Activity: Do NAD+ Precursors Improve Athletic Performance in Children?

NMN and NR have not been shown to improve physical performance in children. The question of whether they could theoretically help is complicated by the fact that children's mitochondrial density and aerobic capacity are already developing rapidly through normal growth, not through NAD+ depletion.

Mitochondrial Development in Childhood

Mitochondrial biogenesis in children proceeds through normal growth signaling driven by IGF-1, growth hormone, and thyroid hormone axes [13]. These pathways are active and intact in healthy school-age children. Introducing exogenous NAD+ precursors at pharmacological doses could theoretically interact with SIRT1-mediated deacetylation of PGC-1alpha, a key regulator of mitochondrial biogenesis [3], though this interaction has not been studied in a developing human system.

Adult Performance Data Does Not Apply

A 2023 randomized crossover trial by Liao et al. (N=48 adults) found that NMN 300 mg/day for 6 weeks modestly improved aerobic capacity (VO2 max increased by approximately 6.2% vs. 0.7% placebo, P<0.05) in recreational runners aged 27-50 [14]. This population had age-related NAD+ decline. A healthy 9-year-old does not share this physiology.

Supplement Safety in Youth Sports

The American Academy of Pediatrics policy statement on performance-enhancing substances states that "the use of performance-enhancing substances by children and adolescents is of concern," and recommends against ergogenic supplement use in this population given insufficient safety data and the potential for harm [15]. NMN and NR fall under this guidance as unregulated dietary supplements.

Safety Profile: What Risks Are Specific to Children Under 12?

The safety risks of NMN and NR in children are unknown, not established as safe. This distinction matters clinically.

Known Adult Adverse Effects

In adults, NMN and NR are generally well tolerated at doses studied in trials (NMN 250-500 mg/day, NR 250-1000 mg/day). Reported adverse effects in adult trials include mild nausea, flushing at higher NR doses, and transient elevations in liver enzymes at doses above 1,000 mg/day of NR in some participants [16]. The FDA has not approved either compound as a drug, and NMN's status as a dietary supplement was complicated when FDA declared in 2022 that NMN could not be marketed as a dietary supplement because it was under investigation as a drug (IND application on file), though this guidance has been contested and enforcement has been inconsistent [17].

Pediatric-Specific Concerns

Several theoretical but serious concerns apply to children specifically:

Growth axis interactions. SIRT1 and SIRT3, which are activated by elevated NAD+, modulate GH/IGF-1 signaling pathways [13]. Sustained supraphysiologic NAD+ levels in a child could theoretically alter growth plate biology, though no human study has examined this.

Hormonal development. Sirtuins regulate steroidogenesis and adrenal function [3]. The adrenal axis in children under 12 is in an active developmental phase (adrenarche typically begins 6-8 years of age). Interference with sirtuin activity during this period carries undefined risk.

Renal clearance differences. Children have higher glomerular filtration rates per body surface area than adults, but metabolite accumulation patterns for NAD+ breakdown products, including methyl-nicotinamide, have not been characterized in pediatric populations [1].

The Precautionary Standard

The FDA's guidance on pediatric drug safety states that children must not be assumed to tolerate drugs and supplements the same way adults do [7]. The European Food Safety Authority similarly requires specific pediatric safety assessment before making health claims for supplements directed at children. Neither NMN nor NR has undergone this assessment.

What School and Activity Accommodations Actually Help Children With Genuine Energy or Focus Issues?

If a parent's concern is that their child seems tired, unfocused, or underperforming at school or in sports, a structured clinical evaluation is the appropriate first step, not a supplement.

A Clinical Triage Framework for Pediatric Fatigue and Focus

The following evaluation pathway reflects standard pediatric workup for children presenting with fatigue, poor concentration, or reduced exercise tolerance:

1. Rule out correctable deficiencies first. Serum ferritin (target >20 ng/mL in children), complete blood count, 25-OH vitamin D, TSH, and fasting glucose should be assessed before any supplement is considered [12].

2. Assess sleep quality and duration. The CDC recommends 9-12 hours nightly for ages 6-12 [11]. Obstructive sleep apnea affects approximately 1-5% of children and is a correctable cause of daytime fatigue.

3. Evaluate physical activity patterns. The CDC's Physical Activity Guidelines for Americans recommend at least 60 minutes of moderate-to-vigorous aerobic activity daily for children aged 6-17 [11]. Sedentary children often improve significantly with structured activity alone.

4. Consider mental health screening. Anxiety and depression affect approximately 9.4% and 4.4% of children aged 3-17, respectively, per CDC NHIS data [11], and both present with fatigue and inattention that can be mistaken for physical causes.

5. Refer to a pediatric specialist if deficiencies are ruled out. A pediatric endocrinologist or pediatric neurologist can evaluate for rarer conditions such as mitochondrial disease, which is the only context in which NAD+ precursor therapy might eventually have a pediatric evidence base.

What Pediatric Dietitians Recommend Instead

The Academy of Nutrition and Dietetics' pediatric nutrition guidelines recommend meeting NAD+ precursor needs through dietary niacin equivalents, found in chicken, tuna, fortified cereals, and peanuts [16]. Dietary niacin intake in children eating a varied diet already supports adequate NAD+ synthesis through the Preiss-Handler pathway without supplementation.

Regulatory and Legal Considerations for Parents and Clinicians

Neither the FDA nor the FTC has approved any marketing claim linking NMN or NR to pediatric cognitive or athletic benefit. Clinicians prescribing or recommending NMN/NR to children under 12 for these purposes would be doing so entirely off-label, without supporting evidence, and potentially contrary to FDA supplement marketing rules [17].

FDA Stance on NMN as a Dietary Supplement

In 2022, FDA issued a response to a citizen petition stating that NMN is excluded from the dietary supplement definition under 21 U.S.C. 321(ff)(3)(B)(ii) because it was authorized for investigation as a new drug before being marketed as a supplement [17]. This regulatory ambiguity means that NMN products sold over-the-counter exist in a legally contested space, and their quality, purity, and dosing accuracy are not guaranteed by FDA oversight. Third-party testing from organizations like NSF International or USP is the minimum standard for any supplement considered for a child, and even then, efficacy and pediatric safety remain unestablished.

Informed Consent and Clinical Liability

Physicians and naturopathic practitioners recommending NMN or NR for children should document that parents have been informed of the complete absence of pediatric trial data, the regulatory ambiguity, and the theoretical risks outlined above. The American Academy of Pediatrics' Committee on Nutrition guidance states that "supplements should not replace a varied diet" and that "the use of supplements in children requires careful consideration of potential risks and benefits" [10].

Summary of Current Evidence and Clinical Position

The evidence base for NMN and NR in children under 12 is empty for efficacy and incomplete for safety. NAD+ levels in healthy school-age children are not depleted. No randomized trial supports use for cognition, focus, or athletic performance in this age group. Known adult adverse effects at high doses, combined with uncharacterized pediatric risks involving growth, hormonal, and renal physiology, mean the precautionary standard applies firmly here.

Families asking about these supplements deserve honest answers: the science that generated adult interest in NMN and NR does not extend to children, and responsible clinical practice means waiting for pediatric trial data before use. Any child presenting with genuine fatigue, poor school performance, or reduced activity tolerance should receive a structured clinical workup targeting iron status, thyroid function, vitamin D, sleep quality, and mental health before a supplement of any kind is considered.

Children under 12 should not take NMN or NR without direct supervision by a board-certified pediatric physician, and that physician should document the specific clinical indication, the absence of approved alternatives, and ongoing monitoring for adverse effects if use proceeds.